2-dodecylamino-ethanesulfonic acid | 2617-76-7

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 有机磺酸及其衍生物
• 英文名称: 2-dodecylamino-ethanesulfonic acid
• 英文别名: N-Dodecyl-taurin；2-Dodecylamino-aethansulfonsaeure；N-dodecylaminoethane sulfonic acid；Ethanesulfonic acid, 2-(dodecylamino)-；2-(dodecylamino)ethanesulfonic acid
• CAS: 2617-76-7
• 化学式: C₁₄H₃₁NO₃S
• 分子量: 293.471
• InChiKey: BQUAFWQBFICUER-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  19
• 可旋转键数：
  14
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  74.8
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  2-dodecylamino-ethanesulfonic acid 在 五氯化磷 、 sodium carbonate 作用下， 以 四氯化碳 、 乙酸乙酯 为溶剂， 反应 50.0h， 生成 2-Dodecyl-[1,2]thiazetidine 1,1-dioxide
  参考文献：
  名称：

  Champseix, A.; Chanet, J.; Etienne, A., Bulletin de la Societe Chimique de France, 1985, # 3, p. 463 - 472

  摘要：

  DOI：
• 作为产物：
  描述：

  十二烷基伯胺 、 乙烯磺酸乙酯 以 甲醇 为溶剂， 生成 2-dodecylamino-ethanesulfonic acid
  参考文献：
  名称：

  Le Berre; Etienne; Dumaitre, Bulletin de la Societe Chimique de France, 1970, vol. 3, p. 946 - 953

  摘要：

  DOI：

文献信息

• Method of reducing undesirable activities of biological and pharmaceutical products
  申请人：New York Blood Center, Inc.

  公开号：EP0050061A2

  公开（公告）日：1982-04-21

  A method of reducing or suppressing undesirable activities like pyrogenicity, hepatitis infectivity and clotting activation of biological or pharmaceutical products, including plasma protein products, or of products for treating them like sterile filters or chromatographic materials. The products are treated by prolonged contact with a solution or suspension of from about 0,25% to about 10% by weight of a non-denaturating amphiphile.

  一种降低或抑制生物或药物产品（包括血浆蛋白产品）或用于处理这些产品（如无菌过滤器或色谱材料）的热原性、肝炎感染性和凝血活化等不良活性的方法。 处理这些产品的方法是将其与一种非变性亲和剂溶液或悬浮液（按重量计约为 0.25%至约 10%）长时间接触。
• Treatment of biological and pharmaceutical products adsorbed on a solid phase with virus and pyrogen inactivating agents
  申请人：Armour Pharmaceutical Company

  公开号：EP0197554A2

  公开（公告）日：1986-10-15

  A method for treating a biological or pharmaceutical product to inactivate viruses and pyrogens therein comprising the steps of adsorbing said product onto a solid phase; treating the adsorbed product with a virus or pyrogen inactivating agent; separating the solid phase and quantitatively removing the residual inactivating agent therefrom; and recovering said product.

  一种处理生物或药物产品以灭活其中病毒和热原的方法，包括以下步骤：将所述产品吸附到固相上；用病毒或热原灭活剂处理吸附的产品；分离固相并定量去除其中残留的灭活剂；以及回收所述产品。
• An ultrapurification process for factor VIII:C
  申请人：BAXTER INTERNATIONAL INC. (a Delaware corporation)

  公开号：EP0286323A2

  公开（公告）日：1988-10-12

  A process for purifying polypeptides comprising contacting an immobilized antibody specifically binding a polypeptide with that polypeptide, desorbing the polypeptide from the antibody which had adsorbed it, eluting the polypeptide from the presence of the antibody, passing the eluted polypeptide through an affinity region capable of binding the polypeptide, binding the polypeptide in the affinity region and passing contaminants through said region, and eluting the purified polypeptide.

  一种纯化多肽的工艺，包括将特异性结合多肽的固定化抗体与多肽接触，从吸附了多肽的抗体中解吸多肽，将多肽从抗体中洗脱出来，将洗脱出来的多肽通过能够结合多肽的亲和区，在亲和区中结合多肽并将杂质通过所述区域，然后洗脱纯化的多肽。
• [DE] VERFAHREN ZUR VIRUSINAKTIVIERUNG IN GEGENWART VON POLYALKYLENGLYKOL SOWIE DIE DABEI ERHALTENE PHARMAZEUTISCHE PRÄPARATION<br/>[EN] PROCESS FOR VIRUS DEACTIVATION IN THE PRESENCE OF POLYALKYLENE GLYCOL AND THE PHARMACEUTICAL PREPARATION THUS OBTAINED<br/>[FR] PROCEDE PERMETTANT D'INACTIVER UN VIRUS EN PRESENCE DE POLYALKYLENEGLYCOL ET PREPARATION PHARMACEUTIQUE AINSI REALISEE
  申请人：IMMUNO AKTIENGESELLSCHAFT

  公开号：WO1995009657A1

  公开（公告）日：1995-04-13

  (DE) Die Erfindung betrifft eine pharmazeutische Präparation, enthaltend ein Plasmaprotein, welche Präparation frei von infektiösen Agenzien sowie weitgehend frei von Denaturierungsprodukten ist und erhältlich ist durch ein Verfahren, das die folgenden Schritte umfaßt: a) Zugabe eines Polyethers zu einer das Plasmaprotein enthaltenden Lösung, gegebenenfalls Lyophilisierung der Lösung, b) Inaktivierung von infektiösen Agenzien in Gegenwart des Polyethers durch eine physikalisch-chemische oder chemische Behandlung, und c) Entfernung des Polyethers.(EN) The invention relates to a pharmaceutical preparation containing a plasma protein, said preparation's being free form infectious agents and largely free from denaturing products and obtainable by a process comprising the following steps: a) addition of a polyether to a solution containing the plasma protein, with possible lyophilisation of the solution; b) deactivation of infectious agents in the present of the polyether by a physical-chemical or chemical treatment; and c) removal of the polyether.(FR) L'invention concerne une préparation pharmaceutique contenant une protéine plasmatique, qui est exempte d'agents infectieux ainsi que, dans une large mesure de produits de dénaturation. Cette préparation s'obtient selon un procédé comprenant les étapes suivantes: a) addition d'un polyéther à une solution contenant la protéine plasmatique, éventuellement lyophilisation de la solution; b) inactivation des agents infectieux en présence du polyéther par traitement physico-chimique ou chimique, et c) élimination du polyéther.

  该发明涉及一种医药制剂，包含一种血浆蛋白，所述制剂不含感染性病原体，且基本不含变性产物，可通过下列步骤制备：首先，我们会将一种多聚醚加入含有血浆蛋白的溶液中，可对溶液进行 lyophilisation 处理；然后，我们在多聚醚的环境下对感染性病原体进行物理-化学或化学处理以达到去污效果；最后，我们会去除多聚醚。
• Malignant Pericardial Effusion
  作者：Adolfo García-Riego、César Cuiñas、Juan José Vilanova

  DOI：10.1159/000327865

  日期：——

  OBJECTIVE: To examine the frequency and diagnostic implications of malignant pericardial effusions.STUDY DESIGN: The clinical and histologic records of pericardial effusions diagnosed cytologically as malignant were reviewed. We investigated the relationship between malignancy and type of tumor, interval between diagnosis of the primary tumor and development of the pericardial effusion, and length of survival after the onset of the effusion.RESULTS: There were 375 pericardial effusions among 23,592 effusions studied over 24 years; 65 of them were diagnosed as malignant. The mean age at onset was 53.6 years. In 92% of the cases the primary tumor was epithelial, lung the most frequent in males and breast in females. In 48% of cases the pericardial effusion constituted the first sign of malignancy.CONCLUSION: Diagnosis of a pericardial effusion as malignant carried an ominous prognosis: 86% of patients died within the first year and nearly one-third within the first month. Breast carcinomas were linked with the longest survival and longest interval of latency prior to the onset of the pericardial effusion. There were two effusions associated with lymphoblastic lymphomas; they have had no recurrence 10 and 17 years after the effusion, and the patients can be considered cured.